Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)

Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)

Abstract Background Plasmodium vivax forms dormant liver stages that can reactivate weeks or months following an acute infection. Recurrent infections are often associated with a febrile illness and can cause a cumulative risk of severe anaemia, direct and indirect mortality, and onward transmission...

Full description

Bibliographic Details
Main Authors: Kamala Thriemer, Tamiru Shibru Degaga, Michael Christian, Mohammad Shafiul Alam, Benedikt Ley, Mohammad Sharif Hossain, Mohammad Golam Kibria, Tedla Teferi Tego, Dagimawie Tadesse Abate, Sophie Weston, Amalia Karahalios, Megha Rajasekhar, Julie A. Simpson, Angela Rumaseb, Hellen Mnjala, Grant Lee, Rodas Temesgen Anose, Fitsum Getahun Kidane, Adugna Woyessa, Kevin Baird, Inge Sutanto, Asrat Hailu, Ric N. Price
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Trials
Subjects:
Vivax malaria
Falciparum malaria
Radical cure
Universal radical cure
Vivax elimination
Co-endemic
Online Access:https://doi.org/10.1186/s13063-022-06364-z

Internet

https://doi.org/10.1186/s13063-022-06364-z

Similar Items